ERBB2 and breast carcinoma: After proven benefit for patients with advanced HER2-positive breast cancer, anti-HER2 therapies were evaluated for early disease.(6,7) In 2005, Piccart-Gebhart et al. evaluated treatment with one to two years of trastuzumab in HER2- positive early breast cancer with prior neoadjuvant or adjuvant therapy, showing an overall survival benefit of one year against the observational group.(8)